Streetbeat News

Price Targets

DXCM

Baird analyst Jeff Johnson has maintained an 'Outperform' rating on DexCom (NASDAQ:DXCM) but lowered the price target from $153 to $130.

Portfolio Pulse from Benzinga Newsdesk

August 21, 2023 | 10:23 am

TNDM

Baird analyst Jeff Johnson has maintained a Neutral rating on Tandem Diabetes Care (NASDAQ:TNDM) and lowered the price target from $33 to $32.

Portfolio Pulse from Benzinga Newsdesk

August 21, 2023 | 10:22 am

NVDA

HSBC analyst Frank Lee maintains a Buy rating on NVIDIA and raises the price target from $600 to $780.

Portfolio Pulse from Benzinga Newsdesk

August 21, 2023 | 10:18 am

VIPS

HSBC analyst Charlene Liu maintains a 'Hold' rating on Vipshop Holdings (NYSE:VIPS) and raises the price target from $13.8 to $14.2.

Portfolio Pulse from Benzinga Newsdesk

August 21, 2023 | 10:17 am

FTCH

Citigroup analyst Catherine O'Neill maintains a 'Sell' rating on Farfetch (NYSE:FTCH) and lowers the price target from $4.3 to $3.

Portfolio Pulse from Benzinga Newsdesk

August 21, 2023 | 10:15 am

CALT

HC Wainwright & Co. analyst Edwin Zhang has reiterated a 'Buy' rating on Calliditas Therapeutics (NASDAQ:CALT) and maintained a $50 price target.

Portfolio Pulse from richadhand@benzinga.com

August 21, 2023 | 10:08 am

BPMC

Needham analyst Ami Fadia maintains a 'Buy' rating on Blueprint Medicines (NASDAQ:BPMC) and raises the price target from $65 to $66.

Portfolio Pulse from richadhand@benzinga.com

August 21, 2023 | 10:03 am

PODD

Citigroup analyst Joanne Wuensch has upgraded Insulet (NASDAQ:PODD) from Neutral to Buy, but lowered the price target from $273 to $265.

Portfolio Pulse from richadhand@benzinga.com

August 21, 2023 | 9:34 am

GAME

Roth MKM analyst Sean McGowan has initiated coverage on GameSquare Holdings (NASDAQ:GAME) with a Buy rating and a price target of $7.

Portfolio Pulse from richadhand@benzinga.com

August 21, 2023 | 9:29 am

MPW

JP Morgan analyst Michael Lapides has downgraded Medical Properties Trust (NYSE:MPW) from Neutral to Underweight and lowered the price target from $9 to $7.

Portfolio Pulse from richadhand@benzinga.com

August 21, 2023 | 9:27 am